Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

NCT03546829

Status	RECRUITING
Phase	Phase 1
Sponsor	Abramson Cancer Center at Penn Medicine
Enrollment	10 participants

Plain Language Summary

This trial is studying whether taking antibiotics around the time of precision radiation therapy (called SBRT — a focused, high-dose form of radiation) affects how well the treatment works in patients with non-small cell lung cancer, potentially through changes to gut bacteria.

You may be eligible if...
- You are over 18 years old
- You have non-small cell lung cancer (either confirmed by biopsy or suspected based on scans)
- You are scheduled to receive SBRT or a similar ablative (high-dose focused) radiation treatment
- You are able to give informed consent

You may NOT be eligible if...
- You have taken antibiotics, antifungals, antivirals, or antiparasitics in the 4 weeks before enrolling
- You have an active infection with a fever
- You have been on steroids, methotrexate, or other immune-suppressing drugs in the past 4 weeks
- You recently had chemotherapy or will have it during the radiation period
- You have a history of HIV, hepatitis B, or hepatitis C
- You have uncontrolled inflammatory bowel disease, persistent diarrhea, or a recent C. difficile infection
- You have had major bowel surgery in the past 5 years
- You currently take anti-diarrheal medications or probiotics

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (28)

- Randomized Pilot Inclusion
- Patients planned to receive Stereotactic Body Radiotherapy (SBRT) to a biopsy-proven or clinically-suspected NSCLC
- Age \>18 years' old
- Patient capable of giving informed consent
- Randomized Pilot Exclusion

... and 23 more (see full listing online)

Locations (1 total)

University of Pennsylvania, Philadelphia, Pennsylvania, United States